Your browser is no longer supported. Please, upgrade your browser.
Settings
SBBP [NASD]
Strongbridge Biopharma plc
Index- P/E- EPS (ttm)-0.73 Insider Own3.50% Shs Outstand67.38M Perf Week1.05%
Market Cap195.31M Forward P/E- EPS next Y-0.12 Insider Trans0.00% Shs Float59.82M Perf Month26.75%
Income-44.20M PEG- EPS next Q-0.10 Inst Own62.40% Short Float3.14% Perf Quarter-13.47%
Sales32.40M P/S6.03 EPS this Y14.80% Inst Trans-11.19% Short Ratio1.39 Perf Half Y4.33%
Book/sh0.83 P/B3.48 EPS next Y69.20% ROA-39.80% Target Price- Perf Year-18.82%
Cash/sh- P/C- EPS next 5Y20.00% ROE-72.50% 52W Range1.87 - 4.63 Perf YTD18.93%
Dividend- P/FCF- EPS past 5Y21.60% ROI-52.20% 52W High-37.58% Beta1.59
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin94.90% 52W Low54.55% ATR0.17
Employees72 Current Ratio3.60 Sales Q/Q25.40% Oper. Margin- RSI (14)61.17 Volatility4.88% 6.41%
OptionableYes Debt/Eq0.00 EPS Q/Q25.10% Profit Margin- Rel Volume0.46 Prev Close2.90
ShortableYes LT Debt/Eq0.31 EarningsMay 12 BMO Payout- Avg Volume1.35M Price2.89
Recom1.80 SMA208.00% SMA5012.51% SMA2007.97% Volume624,531 Change-0.34%
May-25-21Downgrade Craig Hallum Buy → Hold
Mar-03-20Initiated Craig Hallum Buy $7.50
Sep-25-19Initiated Evercore ISI Outperform
Sep-24-19Initiated Jefferies Buy $8
Dec-18-18Initiated Laidlaw Buy $11
Dec-06-17Initiated Cantor Fitzgerald Buy $14
Jan-25-17Reiterated H.C. Wainwright Buy $15 → $18
Apr-25-16Initiated H.C. Wainwright Buy $15
Nov-10-15Initiated Stifel Buy $21
Nov-10-15Initiated JMP Securities Mkt Outperform
Jun-15-21 11:28PM  
11:33AM  
Jun-08-21 11:17AM  
09:06AM  
Jun-05-21 07:55PM  
Jun-04-21 07:00PM  
Jun-03-21 04:01PM  
Jun-01-21 01:59PM  
11:50AM  
May-28-21 09:00PM  
06:01PM  
04:38PM  
May-27-21 02:24PM  
May-25-21 11:13AM  
10:42AM  
May-24-21 07:03PM  
06:25PM  
05:45PM  
04:58PM  
12:43PM  
07:57AM  
05:46AM  
May-13-21 07:30AM  
May-12-21 10:31AM  
07:30AM  
06:45AM  
May-06-21 07:30AM  
May-04-21 06:17AM  
Apr-28-21 12:34PM  
Apr-08-21 06:52AM  
Apr-07-21 04:01PM  
Mar-20-21 11:00AM  
Mar-15-21 07:30AM  
Mar-04-21 11:52PM  
Mar-03-21 08:45AM  
08:28AM  
07:30AM  
06:30AM  
Mar-02-21 10:19AM  
07:30AM  
Feb-25-21 07:30AM  
Feb-16-21 07:00AM  
Feb-03-21 07:30AM  
Jan-06-21 07:00AM  
Jan-04-21 03:29AM  
Dec-14-20 09:56AM  
Nov-24-20 07:30AM  
Nov-12-20 07:30AM  
Nov-10-20 12:42PM  
Nov-03-20 11:52AM  
Oct-29-20 05:35PM  
04:01PM  
03:00PM  
Oct-22-20 07:30AM  
Sep-30-20 06:05PM  
Sep-28-20 10:30PM  
Sep-27-20 01:08AM  
Sep-23-20 10:30PM  
Sep-21-20 09:30PM  
Sep-19-20 05:14PM  
Sep-17-20 08:00AM  
Sep-16-20 11:29PM  
04:35PM  
01:05PM  
Sep-14-20 08:32PM  
11:00AM  
Sep-08-20 08:00AM  
06:30AM  
Aug-28-20 01:37PM  
Aug-04-20 09:05AM  
07:30AM  
Jul-28-20 07:30AM  
Jul-22-20 12:32PM  
Jul-07-20 07:30AM  
Jul-05-20 10:26PM  
Jul-01-20 07:30AM  
Jun-01-20 07:30AM  
May-27-20 11:34AM  
May-20-20 07:30AM  
May-18-20 10:04AM  
07:30AM  
May-15-20 06:33AM  
May-11-20 07:30AM  
May-06-20 09:35AM  
08:25AM  
07:30AM  
Apr-29-20 12:34PM  
Apr-20-20 07:30AM  
Mar-07-20 12:26AM  
Feb-27-20 08:35AM  
07:30AM  
Feb-25-20 08:55AM  
07:30AM  
06:30AM  
Feb-19-20 07:30AM  
Jan-30-20 04:30PM  
Jan-09-20 07:30AM  
Dec-16-19 07:35AM  
Nov-18-19 01:03PM  
07:30AM  
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILL DAVID NDirectorSep 24Buy2.138,00017,04074,896Sep 28 07:48 AM
CDK ASSOCIATES, L.L.C.10% OwnerSep 18Buy2.206,00013,2008,060,682Sep 21 09:48 PM
CDK ASSOCIATES, L.L.C.10% OwnerSep 17Buy2.251,473,3773,315,0988,054,682Sep 21 09:48 PM